Takeda Launches Subsidiary in Ecuador
Takeda Pharmaceuticals International GmbH has launched a wholly- owned subsidiary in Ecuador which will be responsible for the sales and marketing of Takeda’s products in the country.
With a direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia and Ecuador, the company is continuing to look at opportunities to further expand its footprint in Latin America. According to IMS Health, pharmaceutical sales in Latin America totaled US$ 74.5 billion in 2012 and are expected to grow at a compound annual rate of 8%* between 2012 and 2016. Takeda plans to outgrow the market over the same period, it reports.
Driven by government investment and strong oil and mining industries, Ecuador represents a dynamic and growing market The country’s GDP totalled more than US$ 70 billion in 2012 while pharmaceutical sales in amounted to US$1.27 billion and are expected to continue to grow by 10% during 2013*. Takeda is building a product portfolio based on the medical needs of the population, focusing on gastroenterology,
cardiology, metabolism, oncology and respiratory diseases.
Carlos Haro, who has been appointed country manager for Ecuador, joins the Company from Sanofi, where he was the General Manager for Ecuador. He will lead the start-up team which will grow steadily as the Company expands its portfolio and enters new therapeutic areas.
“The launch of our subsidiary in Ecuador reinforces Takeda’s position in Latin America and will enable us to meet the diverse healthcare needs of the population. We have an established product portfolio, which will give us a strong starting point and we look forward to launching our novel medicines into the market,” said Norbert Oppitz, Senior Vice President, Latin America, at Takeda. “This investment further demonstrates our commitment to Latin America and its growth potential. We have ambitious plans in this region and we continue to evaluate opportunities to expand our footprint.”
*Data Source: ©2012 IMS Health. All rights reserved. Estimate based on Market Prognosis Global 2012-2016.
Norbert Oppitz Carlos Haro MORE INFO. 60
Xceleron and JCL Bioassy Offer Combined Solutions for Clinical Investigations
Xceleron, a specialist in the design and use of ultra-sensitive Accelerator Mass Spectrometry (AMS) in novel clinical investigation and JCL Bioassay, a leader in the use of highly sensitive LC-MS/MS and proprietary methodologies, have partnered to offer drug developers across Asia, Europe and North America access to their analytical platforms in early clinical development.
The partnership provides access to clinical design expertise and the most appropriate technologies for investigations. Xceleron and JCL Bioassay have between them developed over 100 analytical methods for Phase 0 and enriched Phase 1 investigations and both companies have recently built, equipped and staffed laboratories specifically for the purpose of ultra-low level analyses under GLP and GCP conditions.
“This partnership emphasises the critical role of contemporary analytical platforms in driving down the cost of drug development. Whether in Phase 0 or enriched Phase I, we can confidently provide critical PK and PD information before Phase II” said Dr Michael Butler, CEO of Xceleron.
“With 27 years’ experience in providing services for bioassay work coupled with-state-of-the-art analytical instruments, our researchers are well positioned to conduct ultrasensitive bioanalyses. This has led to the continuous growth of our company as a leader in the bioanalytical field and enables our customers to make rapid and precise decisions on their drug development programs. The partnership with Xceleron further expands the geographic and technological scope of the services we can provide to our customers and promotes the use of these cutting-edge analytical platforms to detect low level analytes in early drug development” said Jenny Lin, Vice President of Operations and CSO of JCL Bioassay USA, Inc.
MORE INFO. 62 Analytik Jena AG Acquires UVP
Analytik Jena AG has signed a contract for the acquisition of all shares of UVP LLC based in Upland, California, USA. The transfer of shares will also mean that Analytik
Jena AG acquires UVP’s wholly owned subsidiary, Ultra-Violet Products Ltd based in Cambridge, Great Britain.
The parties have agreed not to reveal the purchase price. UVP is a globally-operating provider of predominantly digital imaging systems for applications in proteomics, genomics and plant and animal sciences.
The UVP group reported sales of around US$17.2 million during the 2012 financial year with almost half the sales generated in North America. The Group has 109 employees worldwide.
The integration of UVP into the Analytik Jena Group will provide an entry into the US market through its Life Sciences Business unit.
The Company is already aiming to reach an operating result (EBIT) above breakeven for the 2nd half of financial year 2012/2013 and expects sales above €40.0 million and operating earnings of 4.0 % to 7.0
%.for the financial year 2013/2014.
MORE INFO. 61
Leading Polish Institute Installs Advanced EB System
The Institute of Electronic Materials Technology (ITME) in Warsaw has purchased a high performance electron beam lithography system from Vistec Electron Beam GmbH to assist with research and manufacturing of micro-optical and diffractive elements, new materials and masks for optical lithography.
"We selected Vistec's electron-beam writer to support our research, development and manufacturing efforts due to its high performance and flexibility. We anticipate that the new Vistec SB251 will significantly contribute to successfully meet our research and development agenda.", said Dr Zygmunt Luczynski, Director of ITME. The decision was made as a result of a European tendering procedure.
The Vistec SB251 is a universal system, which offers both direct write
as well as mask making exposures, enabling lithography below 50nm on various substrates from pieces up to 200mm wafers and 7inch masks. The system also features EQUIcon GmbH’s ePLACE data preparation software package.
"With the Vistec SB251 our long term partner ITME receives an advanced electron-beam lithography system. Due to its high flexibility and reliability the SB251 is perfectly tailored to the diversified applications ITME is facing now and will be challenged with in the future.", comments Wolfgang Dorl, General manager of Vistec Electron Beam. "We are very pleased that ITME placed the order with Vistec, which further continues our successful collaboration started more than 20 years ago."
MORE INFO. 63 OGT to Develop Prostate Cancer Biomarker Panel
Oxford Gene Technology (OGT), a provider of genetics research and biomarker development has been granted a licence by The Institute of Cancer Research (ICR), London, to further develop and commercialise a new panel of diagnostic and prognostic microRNA biomarkers for prostate cancer. The agreement follows a three-year collaboration between OGT and the ICR resulting in the joint discovery of the microRNA biomarkers. These markers have wide- ranging potential applications in diagnosis, prognosis, treatment planning and patient monitoring.
Professor Colin Cooper Dr Mike Evans
Unlike the present screening techniques, the biomarkers discovered by OGT and the ICR have a specificity of over 90% plus the potential to not only identify prostate cancer but also to assess its aggressiveness. This is important as it will allow treatment to be tailored to specific features of the cancer. At present, a diagnosis of prostate cancer can mean removal of the prostate and chemotherapy; patients with
indolent cancer often receive, but do not require, such excessive treatment.
Dr Mike Evans, CEO at OGT, said: “We look forward to continuing our work with the ICR and developing this biomarker panel further. We are hopeful that these biomarkers will change the way that patients with prostate cancer are treated. OGT has a rapidly expanding portfolio of biomarkers for early disease detection which includes highly prevalent cancers of major clinical significance, including colorectal cancer.”
Colin Cooper, Professor of cancer genetics at the University of East Anglia, who led the study at the ICR, said: “OGT and the ICR have made significant progress. Prostate cancer is the most common type of cancer in men with over 240,000 new cases diagnosed each year in the US alone; we need to focus our efforts not only on ensuring accurate diagnosis but also individualised treatment tailored by prognosis."
MORE INFO. 64 Win a Free 405 Touch Microplate Washer with Verify Technology!
The only thing better than our 405£ Touch Microplate Washer with Verify£ Technology is winning a FREE one! Enter to win from April 1 to June 30, 2013 by visiting:
www.biotek.com/405touchgiveaway Only one entry per person will be accepted, and the winner will be randomly drawn from all global entries.
MORE INFO. 65
Read all the latest News & Views, Articles and New Product Releases Online, visit:
www.labmate-online.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
